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Epigenetic aberrations are now well established in the development and 
 progression of ovarian cancer, including DNA methylation, histone modifications, 
and microRNA dysregulation, and their progressive accumulation is correlated with 
the progression of the stage grade of disease. Epigenetic aberrations are relatively 
stable, linked to various subtypes of the disease, and present in circulating serum, 
representing promising diagnostic, prognostic, and pharmacodynamic biomark-
ers. Unlike DNA mutations and deletions, aberrant gene-repressive epigenetic 
changes, including DNA methylation inhibitors or histone-modifying enzymes, 
are theoretically reversible by epigenetic therapies. While no action against solid 
tumors, including ovarian cancer, has been shown in epigenetic monotherapies, 
preclinical studies indicate that they may be successful when used in conjunction 
with one another or with conventional chemotherapy, and combinatorial epigenetic 
therapy regiments are being investigated in cancer clinical trials. Improved inter-
ventions against this debilitating malignancy will provide a greater understanding 
of  epigenetics’ role in ovarian cancer.
Keywords: ovarian cancer, epigenetic, miRNA, DNA methylation,  
histone modification
1. Introduction
Among gynecological malignancies, ovarian cancer, a molecularly heterogeneous 
condition associated with poorest prognosis. The highest mortality rates are associ-
ated with ovarian cancer, reflecting the third most prevalent cancer in female carci-
nomas of the gynecologic system. While it accounts for just 3% of all female cancers, 
the worldwide annual prevalence of ovarian cancer is 220,000, with 21,750 reported 
new cases and 13,940 estimated deaths annually [1]. Specific diagnosis in more than 
70% of OC cases is a potent factor for high fatality rates at an advanced disease stage 
and carries a poor prognosis with current therapies. In ovarian cancer, the median 
age of disease diagnosis is 60 years and its lifetime incidence is one in seventy with 
estimated lifetime mortality of one in ninety-five [2, 3]. Epithelial ovarian cancer 
(EOC) accounts for 90% of all types of OC cases distinguished at histopathological, 
clinical, and molecular levels by heterogeneity. The precise cause of the malignancy 
of the ovaries is still unclear. Significant risk factors associated with OC have been 
identified as a strong family history of either ovarian or breast cancer. More than 
one-fifth (approximately 23%) of ovarian carcinomas have inherited susceptibility 
and have BRCA1 and BRCA2 tumor suppressor gene mutations [4].
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Rapid growth, unspecific clinical symptoms at the early stage of the disease, and 
the absence of earlier diagnosis methods make it challenging to diagnose promptly 
due to lack of effective screening. As a result, when the tumor has spread beyond 
the pelvis and is unlikely to be entirely removed by surgery, EOC is usually diag-
nosed at an advanced stage (FIGO III/IV). Long-term survival rates are poor (10–30 
percent for women with disseminated malignancies. However, an ovarian cancer 
diagnosis at the localized level is considerable curable (over 95 percent five-year 
survival rate; [5]). Therefore, it is needed to explore cost effective and sensitive 
screening program for early detections and biomarkers to predict disease behaviors 
and responses to therapies. In identifying promising biomarkers of clinical util-
ity for early diagnosis of OC, a better understanding of the EOC genome portrait 
would benefit.
Altered epigenetic states are closely associated with tumorigenesis of the ovaries. 
Epigenetics is characterized as a heritable alteration in gene expression without the 
DNA sequence itself being altered and involves DNA methylation, histone modifi-
cation, nucleosome repositioning, and micro-RNAs (miRNAs) posttranscriptional 
gene regulation [6, 7]. Cancer vulnerability is inherited, but most of this inherit-
ability remains unknown. Epigenetic changes in the parental germ line that do 
not require transmission of genetic variants from parent to offspring may mediate 
such missing heritability. DNA methylation, the addition of a methyl moiety to 
the cytosine-5 location within the sense of a CpG dinucleotide, mediated by DNA 
methyltransferases (DNMTs), is the most studied epigenetic shift [6]. While most 
CpG sites are methylated in the human genome, CpG-dense regions known as CpG 
islands (often gene-associated) are usually unmethylated in normal tissue. Also, 
histone proteins associated with DNA are subject to extensive modifications that 
mediate the assembly of chromatin that is transcriptionally permissive or restric-
tive (i.e., open or closed). DNA methylation and histone modifications are now 
recognized to be closely related [6]. The complete epigenetic state corresponding 
to a particular cell phenotype (e.g., DNA methylation, histone modification, and 
miRNA expression) is now referred to as the epigenome [8]. Though repressive epi-
genetic changes (including DNA methylation) control genes in normal tissues (e.g., 
imprinted genes and inactivation of female X-chromosomes), they are dramatically 
altered in cancer [6, 9]. Global DNA hypomethylation and localized hypermethyl-
ation of promoter-associated CpG islands occur primarily in cancer cells, with the 
latter acting as a replacement for point mutations or deletions to induce transcrip-
tional silencing of tumor suppressor genes [6].
2. DNA methylation in ovarian cancer
The substantial shortcomings of the therapies examined above in the treatment 
of ovarian cancer have set the stage for the use, either alone or in combination 
with other therapies, of novel epigenetic therapies to treat this disease. By adding a 
methyl group to stimulate regions of DNA to silence gene expression, the epigenetic 
alteration of DNA methylation controls gene expression. This mechanism is critical 
during sensitive cellular processes, such as embryonic development, inactivation 
of X-chromosomes, and genomic imprinting. The organ’s normal development and 
maturation are determined by a precise balance of active and silenced genes [10]. On 
the other hand, cancer promotes global hypermethylation of CpG islands associated 
with promoters, which are typically unmethylated in normal tissue, silencing genes 
essential for cellular homeostases, such as genes suppress tumors. To promote tumori-
genesis, aberrant DNA methylation and structural chromatin changes will alter gene 
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expression [11]. A repressive and tightly woven chromatin structure is caused by 
DNA methylation, which can minimize gene expression in DNA repair, apoptosis, 
differentiation, drug resistance, angiogenesis, and metastasis. In cancer, gene pro-
moters’ hypermethylation causes the genes involved in cell cycle control, including 
BRCA1, CDKN2A, RASSF1A, LOTI, DAPK, ICAM-l, PALB2, RAD51C, and BRIP1 to 
be downregulated. Therefore, substantial loss of CpG hypermethylation in ovarian 
cancer is correlated with cancer cell growth inhibition [12].
In ovarian cancers, hypermethylation of particular gene promoters has been 
established. Compared to non-neoplastic tissues, promoter hypermethylation 
of tumor suppressors BRCA1 and RASSF1A were significantly higher in ovarian 
cancers [13]. This hypermethylation silences expression to suppress BRCA1 activ-
ity, driving genomic instability in ovarian cancers, analogous to the mutations in 
BRCA1 discussed earlier. RASSF1A encodes a protein controlling the cell cycle; 
silencing this gene promotes cell-cycle progression and unregulated cell develop-
ment. Compared to benign cases, tissues from patients with serous and non-serous 
EOC display significantly higher RASSF1A promoter methylation. [14]. In clear-cell 
ovarian cancer, hypermethylation is also observed. 22 separate CpG loci associated 
with nine genes (VWA1, FOXP1, FGFRL1, LINC00340, KCNH2, ANK1, ATXN2, 
NDRG21 and SLC16A11) were hypermethylated. Inversely associated with tumor 
gene expression, multiple loci methylation, most notably KCNH22 (HERG, a 
potassium channel). Loss of KCNH2 (HERG) expression by methylation may be a 
good prognostic marker, provided that overexpression of the Eag family members 
of the potassium channel promotes increased proliferation and results in poor 
prognosis [15]. However, superficial cell carcinomas also suppress methylation of 
the gene encoding the HNF1B transcription factor, while this gene is methylated 
in high-grade serous ovarian cancers [16]. In invasive carcinomas, Makarla et al. 
found hypermethylation of eight cancer-related genes (p16, RARβ, E-cadherin, 
H-cadherin, APC, GSTP1, MGMT, and RASSF1A) was significantly higher com-
pared to non-invasive cancers and benign cystadenomas [17].
3. Histone modification in ovarian cancer
Chromatin modifying enzymes are altered in ovarian cancers beyond DNA 
methylation. High levels of H3K9 methyltransferase G9a, which adds histone 
methyl groups (H3K9) to promote the compact structure of chromatin and silence 
genes, have been associated with late-stage high-grade and serous ovarian cancer, 
as well as shorter survival in patients with ovarian cancer [18]. Genes marked by 
the chromatin modifications of activating H3K4me3 and silencing H3K27me3 are 
identified as “poised” or bivalent; these are not transcribed into embryonic stem 
cells but resolved as differentiated stem cells into active and transcribed (H3K4me3) 
or silenced and not transcribed (H3K27me3). In 499 high-grade serous ovarian 
cancers, compared to eight normal fallopian tube samples, these bivalent chromatin 
loci were silenced and included genes in the PI3K and TGF-beta signaling pathways. 
Stem-like cells of ovarian cancer and chemo-resistant cells of ovarian cancer have 
demonstrated increased silencing of these genes [19]. As previously mentioned, 
the gene encoding the ARID1A chromatin remodeler is mutated in over 50 percent 
of ovarian clear cell carcinomas. In a mouse model of ovarian cancer, Bitler et al. 
showed inhibiting EZH2 methyltransferase, which adds the H3K27me3 mark to 
silence gene expression, induced regression of ARID1A-mutated tumors. This 
occurred via PIK3IPI upregulation, an ARID1A and EZH2 target increased by EZH2 
inhibition and inhibits PI3K/Akt oncogenic signaling [20].
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4. MicroRNA dysregulation in ovarian cancer
The most recently discovered epigenetic miRNAs represent ovarian tumors have 
recently become a phenomenon, and it was found to substantially up-regulate miR-
199a, miR-200a, miR-200a, miR-214, and down-regulate miR-100 and, precisely, 
miR-100 and miR-214 to target the tumor suppressor, miR-214 was shown to PTEN 
and is associated with resistance to platinum [21, 22]. Let-7 miRNA family as one of 
the regulator of the MYCN pathway that linking to the platinum-resistant trait. It 
was recently discovered that miRNA let-7i was a tumor substantially down-regulated 
suppressor in platinum-resistant ovarian tumors, and restored let-7i gain-of-function 
chemoresistant ovarian cancer drug sensitivity cells, thus representing a biomarker 
and therapeutic candidate goal [23]. MiR-429, miR-200a, and miR-200b, respectively 
a single primary transcript was found to be clustered on epithelial-to-mesenchymal 
transition-regulated (EMT, a metastatic phenotype) ZEB1/SIP1 repressor, with 
negative regulation of miR-200a and miR-200b ZEB1/SIP1 and the development of 
a loop of double-negative feedback [24]. In another study, 27 miRNAs were substan-
tially correlated with chemotherapy response, indicating a chemotherapy response 
miRNA (similar to DNA methylation) represent potential biomarkers for ovarian 
prognosis and diagnosis [25]. Regarding the regulation of miRNA genes, a group of 
six chromosomes, 19 miRNAs clustered on chromosome 19, and seven clusters were 
up-regulated on chromosome 14, DNMT-inhibitor decitabine inhibitor, showing that 
miRNAs can be controlled by DNA methylation [26]. What’s more, an overall, col-
lective tumor—MiRNAs’ suppressive effect has been suggested by Drosha and Dicer 
down-regulation, involving two enzymes in the processing of miRNA, being signifi-
cantly connected with an early stage of ovarian cancer and poor prognosis [27, 28].
5. Epigenetic biomarkers for ovarian cancer
As mentioned above, the development of ovarian cancer is well characterized 
by a range of combinatorial epigenetic aberrations distinct from this malignancy, 
including but not limited to RASSF1A, DAPK, H-Sulf-1, BRCA1, and HOXA10 DNA 
methylation. As a result, these methylated DNA sequences represent potential diag-
nostic, staging, prognostic, and therapy response monitoring (predictive biomark-
ers) biomarkers [29]. DNA methylation biomarkers have several advantages over 
other types of biomarkers, such as proteins, gene expression, and DNA mutations, 
including their stability, ability to amplify (thus greatly enhancing detection sensi-
tivity), relatively low cost of the assessment, and restriction to small DNA regions 
(CpG islands) [30]. It also acts as a biomarker to predict response to platinum-based 
chemotherapy regimen and the poly-ADP ribose polymerase inhibitor (PARPi). In 
the future, DNA methylation tests of resected ovarian tumors are highly likely to 
be used to customize care individually, similar to the recently discovered predictive 
markers of non-small cell lung cancer in stage I [31]. While single-gene methylation 
evaluation lacks adequate specificity for ovarian cancer diagnosis, it is believed that 
multiple methylation biomarker panels will achieve the precision needed for wide-
spread population screening [30, 32]. To that end, a panel of 112 methylated DNA 
markers was found to correlate progression-free survival with ovarian cancer [33].
6. Clinical trials of epigenetic therapeutic in ovarian cancer
DNA methylation inhibitor and HDAC inhibitor are cancer therapeutics, begins 
primarily as a treatment for hematological disorders in the early 2000s. The FDA 
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approved 5-Azacytidine (AZA) and 5-aza-2′-deoxycytidine (decitabine) for 
myelodysplastic syndrome (MDS) in 2004 and 2006, while the HDAC suberoylani-
lide hydroxamic acid (SAHA) inhibitor was approved in 2006 for the treatment of 
persistent or cutaneous T cell lymphoma [34]. Epigenetic therapy was initially per-
formed in a clinical trial. It was setting either alone or with the standard in combi-
nation care to resensitize either the tumor to anticancer treatment or avoid therapy 
resistance production. Ultimately, these medications have been tested against 
resilient OC tumors, like both SAHA and AZA clinical trials, ovarian cancer, which 
is platinum-resistant. Although there are no antitumors, the behavior was detected 
after SAHA treatment, and AZA demonstrated the partial reaction. Still, it was 
correlated with significant adverse effects such as tiredness and myelosuppression 
[35]. The HDAC inhibitor, in a related analysis Belinostat, was given to platinum-
resistant patients with ovarian tumors. Still, they have similarly caused significant 
adverse reaction events such as thrombocytopenia, neutropenia, and vomiting, 
leading to the end of the analysis with no clinical advantage over conventional 
therapy [34]. Similarly, in a phase I study, the vorinostat pan-HDACi carboplatin or 
gemcitabine was administered despite the extreme hematological toxicities caused 
and caused observed partial response, leading to the termination of the study [36].
7. Future prospects
Exponential advancement in DNA methylation-based biomarker growth has 
been observed over the last decade. A variety of cfDNA and tissue-dependent 
screening assays have paved their way into clinics due to the consistency of DNA 
and methylation patterns. Several tests for early detection of colon, lung, and pros-
tate cancer are commercial success based on DNA methylation biomarkers. New 
technologies that enable the rapid identification of methylation signatures directly 
from the blood can promote sample-to-respond solutions, allowing molecular 
diagnostics for the next-generation point of care. Besides, ongoing work on liquid 
biopsies together with the latest advanced technologies such as digital PCR, bisulfite 
sequencing, methyl immune precipitation coupled with next-generation sequenc-
ing, and methylation arrays together with advanced statistical data analysis will 
mitigate the complicated problems of non-invasive system creation by overcoming 
the existing challenges to precision medicine.
8. Conclusion
Ovarian cancer causes substantial morbidity and mortality. Owing to unspecific 
signs at the early stage of the disease, their appearance at an advanced stage, and 
poor survival, the difficulty of promptly diagnosing ovarian cancer at its early stage 
remains difficult. Improved methods of detection are, therefore, urgently needed. 
This chapter identifies the possible clinical usefulness of epigenetic signatures such 
as DNA methylation, modifications of histones, and microRNA dysregulation, 
which play an essential role in ovarian carcinogenesis and its use in the development 
of diagnosis, prognosis, and biomarkers for prediction. New treatment options 
separate from conventional treatment options chemotherapy that benefits from 
developments in the understanding of ovarian cancer pathophysiology to enhance 
performance, they are required. Recent work has shown that mutations in epigen-
etic regulator-encoding genes are mutated in ovarian cancer, driving tumorigenesis 
and drug resistance. Several of these modifiers of epigenetics for ovarian cancer 
treatment have emerged as promising drug targets.
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